Rayence Co

Rayence Co Capital Expenditures

The Capital Expenditures (CapEx) of Rayence Co (228850.KQ) as of Oct 22, 2026 is -2.34 B KRW. In the previous year, Capital Expenditures (CapEx) was -8.36 B KRW — a change of -72.04% (higher).

Capital Expenditures

-2.34 BKRW

YoY

-72.04%

Last updated:

Capital Expenditures (CapEx) of Rayence Co is 2025 -2.34 B KRW. Capital Expenditures (CapEx) of Rayence Co was 2024 -8.36 B KRW. It decreases by -72.04% higher compared to the previous year.

The Rayence Co Capital Expenditures history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Expenditures
Date
Capital Expenditures
Jan 1, 2018
-2.59 B KRW
Jan 1, 2019
-7.18 B KRW
Jan 1, 2020
-2.49 B KRW
Jan 1, 2021
-1.91 B KRW
Jan 1, 2022
-1.91 B KRW
Jan 1, 2023
-4.34 B KRW
Jan 1, 2024
-8.36 B KRW
Jan 1, 2025
-2.34 B KRW
The Rayence Co Capital Expenditures history
YEARCapital ExpendituresYoY
-2.34 BKRW-72.04%
-8.36 BKRW+92.63%
-4.34 BKRW+127.13%
-1.91 BKRW+0.06%
-1.91 BKRW-23.34%
-2.49 BKRW-65.32%
-7.18 BKRW+177.20%
-2.59 BKRW-46.70%
-4.86 BKRW-68.13%
-15.26 BKRW+49.32%
-10.22 BKRW+43.33%
-7.13 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Rayence Co Stock analysis

What does Rayence Co do? Rayence Co., Ltd. generates revenue through the manufacturing and sale of x-ray detectors, including TFT and CMOS detectors under brand names such as 1012WCA, 17SCC/SGC, 1215CF, 1501CF, and 0712CF. The company also produces intra oral sensors branded as Ez1.0 and Ez1.5, along with mammography machines under the 1724CM and 2434CM series. These products are distributed to both domestic and international markets, serving healthcare providers and medical facilities that require diagnostic imaging equipment. The primary customers for Rayence's detectors and sensors are hospitals, clinics, and medical imaging centers seeking advanced x-ray technology. The firm's product portfolio targets the medical imaging segment, focusing on applications such as dental diagnostics with intra oral sensors and radiological imaging with mammography machines. Revenue streams are derived from direct sales of these branded products to healthcare institutions across multiple regions. Rayence's business model centers on selling specialized medical imaging equipment under its own brand names, with no mention of third-party partnerships or additional services. The company's revenue is directly tied to the purchase of its branded x-ray detectors, intra oral sensors, and mammography machines by healthcare providers who require high-quality diagnostic tools for patient care. Rayence Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Rayence Co stock

Capital Expenditures (CapEx) of Rayence Co is -2.34 B KRW in 2025.

Capital Expenditures (CapEx) of Rayence Co changed from -8.36 B KRW to -2.34 B KRW, representing a -72.04% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Capital Expenditures (CapEx) Rayence Co since 2006 – with annual values, charts, and detailed analysis.

Capital expenditures represent investments in long-term assets such as property, equipment, and technology. CapEx is essential for maintaining and growing the business.

Capital Expenditures (CapEx)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Capital Expenditures (CapEx)'s Rayence Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Rayence Co

All Key Metrics — Rayence Co